On August 30, 2023 Diverse Biotech reported that it has been granted USPTO patent approval of its novel CUSP synthesis platform creating an entirely new class of drugs that are part-antibody and part-cannabinoid in one new molecule (Press release, Diverse Biotech, AUG 30, 2023, View Source [SID1234634787]). Starting with DBT-50201, its novel PEMBROLIZUMAB compound, Diverse expects to develop multiple treatments for many diseases with highly unmet needs. According to John Patrick, M.D., Executive Vice President and Chief Medical Officer for Diverse Biotech, "We are very excited about being granted our first patent for our monoclonal antibody class of drugs with our flagship drug DBT-50201 which represents a significant advancement for PEMBROLIZUMAB. We expect that our monoclonal drug DBT-50201 will mirror the results we have seen thus far in trials with our Temozolomide drug used to treat Glioblastomas (brain cancer), DBT-30180. We have observed significant increases in potency and efficacy with our CUSP technology averaging about 2,000% when compared to standard chemotherapy alone. Coupled with other potential decreases in toxicity, these results represent a major step forward in the treatment and cure of multiple cancers."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!